Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Shell plc (SHEL), Uber Technologies, ...

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the promotion of Anna Chen, Ph.D., to Partner. Dr. Chen joined FLS in 2018 and has ...

As we hit peak ISA season, AJ Bell looks at five different flavours of income for ISA investors, including some specific ...

NFL star and Jacksonville Jaguars linebacker Chad Muma was diagnosed with Type 1 Diabetes at 13 years old, but that has never ...

Sanofi Indias shares ended Wednesdays trading session on the NSE 0.41% down at Rs 5,600 with a market value of Rs 12.90KCr, ...

US genetic medicines firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...